{"entity":{"id":"ipsoprubart","kind":"drug","name":"Ipsoprubart","aka":["ELA026"],"tldr":"Ipsoprubart is an experimental antibody from Electra Therapeutics, in phase 1 trials for relapsed or refractory T-cell and NK-cell cancers.","summary":"Ipsoprubart (ELA026) is a monoclonal antibody from Electra Therapeutics. Binds SIRP-alpha (SIRPA) and SIRP-beta1 on myeloid cells and SIRP-gamma on T cells to remove activated immune cells that drive disease. Its lead use is secondary haemophagocytic lymphohistiocytosis, an immune disorder that is not a cancer, in a phase 2/3 study. Its cancer use is a phase 1 study (NCT07465835) in relapsed or refractory T-cell and NK-cell malignancies. Whether it works in people has not been established.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"Electra Therapeutics ipsoprubart","url":"https://electra-therapeutics.com/ipsoprubart/"},{"label":"Electra Therapeutics prospectus (424B4), September 2026","url":"https://www.sec.gov/Archives/edgar/data/2088082/000119312526395670/d61940d424b4.htm"},{"label":"ClinicalTrials.gov NCT07465835","url":"https://clinicaltrials.gov/study/NCT07465835"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["sirpa"],"drugs":[],"companies":["electra-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07465835"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"ELA026","modality":"Monoclonal antibody","mechanism":"Binds SIRP-alpha (SIRPA) and SIRP-beta1 on myeloid cells and SIRP-gamma on T cells to remove activated immune cells that drive disease.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ipsoprubart/","neighbours":{"target":[{"id":"sirpa","kind":"target","name":"SIRPA","route":"/targets/sirpa/"}],"company":[{"id":"electra-therapeutics","kind":"company","name":"Electra Therapeutics","route":"/companies/electra-therapeutics/"}],"trial":[{"id":"nct07465835","kind":"trial","name":"A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)","route":"/trials/nct07465835/"}]}}